US
CA
NZ
UK
AU
IND
Last update at 2025-06-12T18:44:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update
Wed 30 Apr 25, 11:00 AMAC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update
Thu 13 Mar 25, 11:00 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -70.74000M | -72.99300M | -61.92100M | 45.44M | -50.95100M |
| Minority interest | - | - | - | 0.00000M | 0.00000M |
| Net income | -70.75300M | -72.99600M | -62.10500M | 45.44M | -50.95100M |
| Selling general administrative | 15.79M | 10.88M | 11.09M | 9.42M | 7.56M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 3.94M | - | 15.43M | 111.03M | 7.19M |
| Reconciled depreciation | 2.36M | 2.41M | 1.97M | 1.69M | 0.96M |
| Ebit | -70.84700M | -79.01000M | -61.26000M | 44.54M | -49.45900M |
| Ebitda | -70.77800M | -70.11900M | -59.21500M | 46.50M | -48.49800M |
| Depreciation and amortization | 0.07M | 8.89M | 2.04M | 1.97M | 0.96M |
| Non operating income net other | - | - | - | 0.00000M | 0.00000M |
| Operating income | -70.84700M | -79.01000M | -61.26000M | 44.54M | -49.55000M |
| Other operating expenses | 74.78M | 79.01M | 76.69M | 66.49M | 56.74M |
| Interest expense | 0.35M | 0.58M | 0.18M | 1.89M | 0.30M |
| Tax provision | 0.01M | 0.00300M | 0.00000M | 0.00000M | 0.00000M |
| Interest income | 0.07M | 6.49M | 0.08M | 0.30M | 0.03M |
| Net interest income | -0.28600M | 5.90M | -0.10600M | -1.62300M | -0.20700M |
| Extraordinary items | - | - | - | 0.00000M | 0.00000M |
| Non recurring | - | - | - | 0.00000M | 0.00000M |
| Other items | - | - | - | 0.00000M | 0.00000M |
| Income tax expense | 0.01M | 0.00300M | 0.18M | 1.89M | -1.10300M |
| Total revenue | 3.94M | 0.00000M | 15.43M | 111.03M | 7.19M |
| Total operating expenses | 74.78M | 79.01M | 76.69M | 66.49M | 56.74M |
| Cost of revenue | - | - | - | 0.00000M | 54.31M |
| Total other income expense net | 0.11M | 6.02M | -0.66100M | 0.91M | -1.19400M |
| Discontinued operations | - | - | - | 0.00000M | 0.00000M |
| Net income from continuing ops | -70.75300M | -72.99600M | -61.92100M | 45.44M | -50.95100M |
| Net income applicable to common shares | -70.75300M | -72.99600M | -61.92100M | 45.44M | -50.95100M |
| Preferred stock and other adjustments | - | - | - | 0.00000M | 0.00000M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 182.81M | 185.94M | 261.44M | 238.74M | 299.25M |
| Intangible assets | 50.42M | 50.42M | 50.42M | - | 0.00000M |
| Earning assets | - | - | - | - | - |
| Other current assets | 7.06M | 4.71M | 4.42M | 5.87M | 4.19M |
| Total liab | 22.17M | 16.95M | 29.46M | 23.26M | 26.81M |
| Total stockholder equity | 160.64M | 168.99M | 231.98M | 215.48M | 272.44M |
| Deferred long term liab | - | - | - | - | 0.00000M |
| Other current liab | 11.09M | 9.42M | 16.74M | 11.09M | 11.80M |
| Common stock | 2.09M | 1.80M | 1.79M | 1.54M | 1.44M |
| Capital stock | 2.09M | 1.80M | 1.79M | 1.54M | 1.44M |
| Retained earnings | -316.19700M | -264.01500M | -200.94200M | -132.85000M | -75.52100M |
| Other liab | - | 3.21M | 7.10M | 7.46M | 7.49M |
| Good will | - | - | - | - | 0.00000M |
| Other assets | - | 0.36M | 0.36M | 0.33M | 0.30M |
| Cash | 78.49M | 31.59M | 82.22M | 160.89M | 193.59M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 13.58M | 11.48M | 20.03M | 14.02M | 17.51M |
| Current deferred revenue | 0.14M | 0.59M | 0.72M | 0.31M | 4.48M |
| Net debt | -74.99700M | -28.78500M | -79.30600M | -158.67000M | -190.68000M |
| Short term debt | 0.67M | 0.55M | 0.57M | 0.44M | 1.09M |
| Short long term debt | - | - | - | - | 0.65M |
| Short long term debt total | 3.50M | 2.80M | 2.91M | 2.22M | 2.91M |
| Other stockholder equity | 474.80M | 431.20M | 431.13M | 346.79M | 346.53M |
| Property plant equipment | - | 7.07M | 8.03M | 6.64M | 6.17M |
| Total current assets | 125.15M | 128.09M | 202.63M | 231.77M | 292.77M |
| Long term investments | 0.36M | 0.36M | 0.36M | - | 0.30M |
| Net tangible assets | - | 118.58M | 181.56M | 215.48M | 272.44M |
| Short term investments | 24.55M | 91.00M | 116.00M | 65.00M | 95.00M |
| Net receivables | 15.67M | 0.80M | 1.40M | 1.92M | 1.40M |
| Long term debt | - | - | - | - | 0.00000M |
| Inventory | -0.62200M | - | -1.40300M | -1.92000M | -1.39900M |
| Accounts payable | 1.68M | 0.93M | 2.00M | 2.18M | 0.14M |
| Total permanent equity | - | - | - | - | 0.00000M |
| Noncontrolling interest in consolidated entity | - | - | - | - | 0.00000M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | 0.00000M |
| Accumulated other comprehensive income | -0.05100M | 0.01000M | - | -5.71700M | -4.52800M |
| Additional paid in capital | - | - | - | - | 0.00000M |
| Common stock total equity | - | - | - | 1.54M | 1.44M |
| Preferred stock total equity | - | - | - | - | 0.00000M |
| Retained earnings total equity | - | - | - | - | 0.00000M |
| Treasury stock | - | - | - | - | 0.00000M |
| Accumulated amortization | - | - | - | - | 0.00000M |
| Non currrent assets other | 0.36M | 0.36M | 0.36M | 0.33M | 6.48M |
| Deferred long term asset charges | - | - | - | - | 0.00000M |
| Non current assets total | 57.66M | 57.84M | 58.81M | 6.97M | 6.48M |
| Capital lease obligations | 3.50M | 2.80M | 2.91M | 2.22M | 2.25M |
| Long term debt total | - | - | - | - | 1.81M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 23.76M | -53.66400M | 30.00M | -66.88500M | -32.03600M |
| Change to liabilities | -1.20300M | 0.34M | -1.98000M | 2.28M | 0.85M |
| Total cashflows from investing activities | 23.76M | -53.66400M | 28.33M | -66.88500M | -32.03600M |
| Net borrowings | -0.56900M | 22.95M | -0.94600M | 50.06M | -0.14100M |
| Total cash from financing activities | -1.34600M | 40.75M | -0.80300M | 49.62M | 109.38M |
| Change to operating activities | -7.26500M | 6.60M | -2.56800M | 3.44M | 0.27M |
| Net income | -70.75300M | -72.99600M | -61.92100M | 45.44M | -50.95100M |
| Change in cash | -50.63000M | -78.67700M | -32.69400M | 37.12M | 32.09M |
| Begin period cash flow | 82.22M | 160.89M | 193.59M | 156.46M | 124.38M |
| End period cash flow | 31.59M | 82.22M | 160.89M | 193.59M | 156.46M |
| Total cash from operating activities | -73.56800M | -65.68900M | -59.51700M | 55.22M | -44.07800M |
| Issuance of capital stock | 0.00000M | 16.72M | 0.10M | 0.00000M | 111.53M |
| Depreciation | 2.36M | 2.41M | 1.97M | 1.69M | 0.96M |
| Other cashflows from investing activities | 0.00200M | -0.02900M | -0.02900M | -0.02900M | -0.17800M |
| Dividends paid | - | - | - | 0.00000M | 0.00000M |
| Change to inventory | - | - | - | 0.00000M | 0.00000M |
| Change to account receivables | 0.04M | -0.09900M | -0.02500M | -0.06800M | 0.70M |
| Sale purchase of stock | -0.00800M | 0.00000M | -0.10000M | 0.07M | 111.53M |
| Other cashflows from financing activities | -0.76900M | 24.54M | 0.14M | 50.04M | -1.81700M |
| Change to netincome | 3.26M | -1.94000M | 5.01M | 2.43M | 4.10M |
| Capital expenditures | 1.24M | 2.63M | 1.71M | 1.89M | 1.86M |
| Change receivables | - | - | - | 0.00000M | 0.00000M |
| Cash flows other operating | - | - | - | 0.00000M | 0.00000M |
| Exchange rate changes | - | - | - | 0.00000M | 0.00000M |
| Cash and cash equivalents changes | - | - | - | 0.00000M | 0.00000M |
| Change in working capital | -8.43200M | 6.84M | -4.57300M | 5.65M | 1.81M |
| Stock based compensation | 3.33M | 4.13M | 4.09M | 2.83M | 2.52M |
| Other non cash items | -0.07200M | -6.19600M | 0.55M | -0.90900M | 1.45M |
| Free cash flow | -74.80700M | -68.32400M | -61.22300M | 53.34M | -45.93600M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ACIU AC Immune Ltd |
-0.06 2.83% | 2.06 | - | - | 18.31 | 1.55 | 10.98 | -3.1365 |
| NVO Novo Nordisk A/S |
2.11 2.68% | 80.84 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
2.40 3.07% | 80.50 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
6.68 1.48% | 459.12 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
5.42 1.05% | 524.02 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It is developing Crenezumab, a humanized, conformation-specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome-related AD; ACI-7104.056, to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it is developing diagnostic programs, consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative disease. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD and NeuroOrphan Tauopathies. Additionally, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Building B, Lausanne, Switzerland, 1015
| Name | Title | Year Born |
|---|---|---|
| Dr. Andrea Pfeifer Ph.D. | Co-Founder, CEO & Director | 1957 |
| Mr. Piergiorgio Donati | Chief Technical Operations Officer | 1971 |
| Dr. Marie Kosco-Vilbois | Chief Scientific Officer | 1958 |
| Mr. Jean-Fabien Monin | Chief Admin. Officer | 1971 |
| Prof. Johannes Rolf Streffer M.D. | Chief Medical Officer | 1969 |
| Mr. Christopher Roberts | Interim CFO & VP of Fin. | NA |
| Mr. Joshua Drumm Ph.D. | Head of Investor Relations | NA |
| Mr. Alexandre Caratsch | Gen. Counsel | 1966 |
| Judith Moore | Global Head of Communications | NA |
| Mr. Julian Snow | VP of U.S. Fin. & Corp. Devel. | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...